Ascletis Pharma Inc.

1672

KYG0520K1094

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 15:47:22 12/03/2026 HKT			5-day change	1st Jan Change
15.39 ^HKD	+0.13%		+5.34%	+35.12%

03-06	Top pharma companies racing to launch a weight-loss pill	RE
02-11	Ascletis Pharma Inc. Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development	CI

Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies

Published on 02/11/2026 at 09:50 am HKT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Ascletis Pharma Inc.

03-06	Top pharma companies racing to launch a weight-loss pill	RE
02-11	Ascletis Pharma Inc. Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development	CI
02-11	Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies	MT
02-11	Ascletis Pharma selects ASC36 for clinical development	RE
02-10	Ascletis Pharma Raises HK$835 Million from Share Placement	MT
02-03	Ascletis Pharma to place 69.3 million shares	RE
02-03	Ascletis Pharma Seeks HK$843 Million via Share Offering	MT
01-30	Ascletis Pharma Says Denifanstat Demonstrates Favorable Safety, Tolerability in Open-label Study	MT
01-30	Ascletis Pharma gets positive topline results from phase III open-label study of denifanstat	RE
01-29	Ascletis Pharma Inc. Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat	CI
01-26	Ascletis Pharma Inc. Announces First Participants Dosed in a 13-Week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes	CI
01-26	Ascletis Pharma Doses First Patients in U.S. Phase 2 Trial for Oral GLP-1 Drug	MT
01-20	Ascletis Pharma Selects Weight-loss Drug for Further U.S. Studies	MT
01-20	Ascletis Pharma Inc. Selects A Next-Generation Once-Monthly Subcutaneously Administered Glp-1R/Gipr/Gcgr Triple Peptide Agonist, Asc37, for Clinical Development	CI
01-05	Hong Kong Stocks Close Mixed; Ascletis Pharma Receives U.S. Nod to Begin Phase II Trial of ASC30	MT

Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.

Employees

208

Sector

Pharmaceuticals

More about the company